Abstract
This article reviews and critiques the use of intravenous tPA for acute stroke. Guidelines on which patients should receive tPA are proposed with a particular emphasis placed on onset time. The current status of other potential stroke therapies are also reviewed, including neuroprotective trials and agents designed to limit reperfusion injury.
MeSH terms
-
Ancrod / adverse effects
-
Ancrod / therapeutic use
-
Brain / blood supply
-
Brain Infarction / diagnosis
-
Brain Infarction / drug therapy*
-
Clinical Trials as Topic
-
Fibrinolytic Agents / adverse effects
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Neuroprotective Agents / adverse effects
-
Neuroprotective Agents / therapeutic use*
-
Reperfusion Injury / diagnosis
-
Reperfusion Injury / prevention & control*
-
Streptokinase / adverse effects
-
Streptokinase / therapeutic use
-
Thrombolytic Therapy*
-
Tissue Plasminogen Activator / adverse effects
-
Tissue Plasminogen Activator / therapeutic use
-
Treatment Outcome
Substances
-
Fibrinolytic Agents
-
Neuroprotective Agents
-
Streptokinase
-
Ancrod
-
Tissue Plasminogen Activator